top of page
Femiguard-Logo--Transparent-background.png
Femiguard woman.jpg

REVERSIBLE FALLOPIAN
TUBE OCCLUSION SYSTEM

 Femigard vision - striving for new horizon in female fertility and sterility.
 Femiguard Vision
Company ID

COMPANY ID

FEMIGUARD2-03.png
“Seed” stage
Founded in 2019, backed by Sanara Ventures and the Israeli Innovation Authority
FEMIGUARD2-07.png
Strong team
Established expertise in medical device development, with top tier industry collaborators
FEMIGUARD2-04.png
Platform Technology

A novel concept for fallopian tubes occlusion.

Applicable to a wide range
of indications

FEMIGUARD2-08.png
Raising Capital

Expected during 2022

Supporting clinical validation

FEMIGUARD2-05.png
IP position

Unique technology protection. establishing significant entry barrier Currently at PCT stage

FEMIGUARD2-06.png
Femtech

Provide unique medical solution for clinical needs

OUR MISSION

FEMIGUARD-12.png
Future Market
Contraception

Non hormonal reversible tubal occlusion in office procedure

FEMIGUARD-11.png
Primary Market
IVF

Improving pregnancy implantation success rates in patients with tubal Hydrosalpinx

Contact Us

CONTACT US

Femiguard  | 13 Zarchin St. Raanana, POB 2219 Israel | oz.talel@gmail.com
  • LinkedIn

Thanks for submitting!

bottom of page